strong>Clovis Oncology Inc., of Boulder, Colo., said it started dosing in the phase II portion of the phase II/III TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study testing rociletinib, its oral, targeted covalent mutant-selective inhibitor of EGFR for the treatment of non-small-cell lung cancer in patients with initial activating EGFR mutations as well as primary resistance mutations T790M.